Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study

BMC Pulmonary Medicine

Table 1 Baseline characteristics of the patients

Age (years)	Sex	PAH diagnosis	Disease duration (years)	NYHA	Hemodynamic parameters			6MWD (m)	Concomitant medication	Duration of PDE5i combination therapy (months)
Age (years)	Sex	PAH diagnosis	Disease duration (years)	NYHA	mPAP (mmHg)	PVR (WU)	CI (L/min/m²)	6MWD (m)	Concomitant medication	Duration of PDE5i combination therapy (months)
41	F	CTD-PAH	5	III	37	7.05	3.09	457	Sil, Be, Am	6
48	F	ASD-PAH	8	III	53	10.43	1.65	336	Sil, Be, Bos	12
38	F	NF1-PAH	9	III	55	13.8	2.29	330	Sil, Be, Bos	13
58	F	HPAH	10	IV	38	7.36	2.88	320	Sil, Epo, Bos	10
23	F	IPAH	3	III	40	7.3	2.94	390	Tad, Epo, Bos	14
26	F	IPAH	7	III	62	7.49	4.39	370	Sil, Epo, Bos	3
45	F	IPAH	4	III	50	12	2.22	267	Sil, Be, Bos	9

CTD: connective tissue disease, ASD: atrial septal defect, NF1: neurofibromatosis 1, HPAH: heritable pulmonary arterial hypertension, IPAH: idiopathic pulmonary arterial hypertension, mPAP: mean pulmonary arterial pressure, PVR: pulmonary vascular resistance, WU: Wood’s units, CI: cardiac index, 6MWD: six-minute walk distance, Sil: sildenafil, Tad: tadalafil, Be: beraprost, Epo: epoprostenol, Bos: bosentan, Am: ambrisentan.

ISSN: 1471-2466